GlassScriptPhysician profile
Justin A Meuse
NPI 1518100742
$4,061.85
in general payments reported to CMS, 2019-2025
33 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.13 · 2020: $100 · 2021: $932 · 2022: $185 · 2023: $1,119 · 2024: $582 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,825.89 | 2022-2025 | Percept PC Brainsense, Sensight |
| Abbvie INC. | $494.73 | 2021-2024 | |
| Ucb, INC. | $236.04 | 2019-2025 | Rystiggo, Fintepla, Zilbrysq |
| Sk Life Science, INC. | $194.11 | 2021-2023 | |
| Amgen INC. | $148.01 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $146.71 | 2021 | |
| Biogen, INC. | $141.55 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $97.25 | 2019-2021 | |
| Emd Serono, INC. | $72.84 | 2021 | |
| Genzyme Corporation | $71.08 | 2021 | |
| Lilly USA, LLC | $64.22 | 2021-2023 | Reyvow, Emgality |
| Eisai INC. | $52.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $49.86 | 2024 | |
| Celgene Corporation | $48.51 | 2021-2023 | Zeposia |
| Alnylam Pharmaceuticals INC. | $46.27 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $40.38 | 2023 | Nuplazid |
| Amneal Pharmaceuticals LLC | $30.70 | 2022-2023 | Rytary |
| Merz Pharmaceuticals, LLC | $29.49 | 2023 | Xeomin |
| Ani Pharmaceuticals, INC. | $26.25 | 2023 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $24.64 | 2025 | Symbravo |
| Livanova USA, INC. | $23.55 | 2022 | |
| Allergan, INC. | $22.32 | 2021 | |
| Upsher-Smith Laboratories LLC | $21.24 | 2021 | |
| Neuropace, INC. | $19.35 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $18.48 | 2020 | |
| Ge Healthcare | $17.90 | 2021 | |
| C2n Diagnostics, LLC | $16.78 | 2025 | Precivityad2 |
| Arbor Pharmaceuticals, INC. | $14.95 | 2021 | |
| Tanabe Pharma America, INC. | $14.52 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.16 | 2022 | |
| Lundbeck LLC | $13.14 | 2023 | Vyepti |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Abbott Laboratories | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Meuse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.